Naltrexone Neuroimaging

Phase 0 Completed 13 enrolled Children's Mercy Hospital Kansas City National Center for Advancing Translational Sciences (NCATS) · collab University of Kansas Medical Center · collab

NaSingle-groupOpen-labelOther

Summary

The purpose of this open-label, pilot study is to evaluate fMRI as a biomarker of opioid antagonism in adolescents with ED. Modulation of brain activation will be examined in regions of interest by fMRI using a food-specific and general reward task in adolescents with ED in a pre/post design.

Timeline

Start: 2021-07-16
Primary completion: 2022-06-15
Completion: 2022-06-30

Publications

Stancil SL, Yeh HW, Brucks MG, Bruce AS, Voss M, Abdel-Rahman S, Brooks WM, Martin LE. Potential biomarker of brain response to opioid antagonism in adolescents with eating disorders: a pilot study. Front Psychiatry. 2023 Jul 10;14:1161032. doi: 10.3389/fpsyt.2023.1161032. eCollection 2023.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Naltrexone	Small molecule	50 mg	Oral

Naltrexone Neuroimaging

Summary

Timeline

Publications

Drugs

Indications